|
1）Wintrobe, MM. Hereditary hemorrhagic telangiectasia. In: Lee GR, Bithell, TC, Forester, J, et al, editors. Wintrobe’s Clinical Hematology. Vol 2. 9th ed, Philadelphia and London: Lee & Febieger; 1993. p.1379-93
|
|
|
|
|
2）Osler W. On a family form of recurring epistaxis associated with multiple telangiectases of the skin and mucous membrane. Bull Johns Hopkins Hosp. 1901; 12: 333-7
|
|
|
|
|
|
3）塩谷隆信，金澤知博．オスラー病：遺伝性出血性末梢血管拡張症．呼吸．1989; 8: 707-12
|
|
|
|
|
4）Begbie ME, Wallace GMF, Shovlin CL. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J. 2003; 79: 18-24
|
|
|
|
|
5）Hodgson CH, Burchell HB, Good AC, et al. Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous fistula: Survey of a large family. N Engl J Med. 1959; 261: 625-36
|
|
|
|
|
|
6）Plachu H, de Chadareivian JP, Bideau A, et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989; 2: 291-9
|
|
|
|
|
|
7）Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000; 91: 66-7
|
|
|
|
|
|
8）Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia. Hum Mutat. 2002; 19: 140-8
|
|
|
|
|
|
9）Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet. 2011; 48: 73-87. doi: 10.1136/jmg.2009.069013. Epub 2009 Jun 23
|
|
|
|
|
|
10）Shovlin CL. Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment. Blood Rev. 2010; 24: 203-19. doi:10.1026/jblre.2010.07.001
|
|
|
|
|
|
11）Cottin V, Chinet T, Lavole A, et al. Pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia. A series of 126 patients. Medicine. 2007; 86: 1-17
|
|
|
|
|
|
12）Berg J, Porteous M, Reinhardt D, et al. Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations. J Med Genet. 2003; 40: 585-90
|
|
|
|
|
|
13）McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994; 8: 345-51
|
|
|
|
|
|
14）Johnson DW, Ber JN, Baldwin MA, et al. Mutations in the activin receptor－like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996; 13: 189-95
|
|
|
|
|
|
15）David L, Feige JJ, Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev. 2009; 20: 203-12
|
|
|
|
|
|
16）森崎裕子，森崎隆幸．遺伝性出血性末梢血管拡張症の責任遺伝子．塩谷隆信，編．遺伝性出血性末梢血管拡張症(HHT)の診療マニュアル．東京： 中外医学社；2011. p.17-22
|
|
|
|
|
|
17）Letteboer TG, Mager HJ, Snijder RJ, et al. Genotype phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet. 2008; 146A: 2733-9
|
|
|
|
|
|
18）Morisaki H, Komiyama M, Yamada K, et al. Mutation analysis of TGF-β pathway genes in hereditary hemorrhagic telangiectasia patients in Japan. Genotype-phenotype correlations in 119 cases. Hematology Reports. 2013; 5(sl): 10
|
|
|
|
|
|
19）Komiyama M, Ishiguro O, Yamada H, et al. Clinical analysis of HHT1 and 23 HHT2 Japanese patients. Hematology Reports. 2013; 5(sl): 12
|
|
|
|
|
|
20）Reilly PJ, Nostrant TT. Clinical manifestations of hereditary hemorrhagic telangiectasia. Am J Gastro. 1984; 79: 363-7
|
|
|
|
|
|
21）Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med. 1998; 158: 643-61
|
|
|
|
|
|
22）Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med. 2004; 169: 994-1000
|
|
|
|
|
|
23）研究代表者 塩谷隆信．厚生労働省科学研究補助金研究報告書（難治性疾患克服事業）「遺伝性出血性末梢血管拡張症（オスラー病）に関する遺伝疫学的検討と診療ガイドラインの作成」平成 22 年度 総括・分担研究報告書．平成 23 年 5 月
|
|
|
|
|
|
24）塩谷隆信，小野寺晃彦，遠藤安行，他．肺動静脈瘻からみたオスラー病．日胸．1989; 48: 815-21
|
|
|
|
|
|
25）塩谷隆信，佐竹將宏，中野真理子，他．家族性肺動静脈奇形を合併した遺伝性出血性末梢血管拡張症(Osler病)．日内会誌．2010; 99: 2529-31
|
|
|
|
|
26）塩谷隆信，佐竹將宏，小野貴広，他．脳動静脈奇形の破裂により突然死した，肺動静脈奇形を伴う遺伝性出血性末梢血管拡張症（オスラー病）の１例．日胸．2005; 64: 940-8
|
|
|
|
|
|
27）寺田 豊，塩谷隆信，渡邊博之，他．多発性肺動静脈瘻を合併した遺伝性出血性末梢血管拡張症の１例．日呼吸会誌. 1999; 37: 915-21
|
|
|
|
|
|
28）Smith JL, Lineback MI. Hereditary hemorrhagic telangiectasia. Nine cases in one negro family, with special reference to hepatic lesions. Am J Med. 1954; 17: 41-9
|
|
|
|
|
|
29）Stecker CRH, Lake CF. Hereditary hemorrhagic telangiectasia. Arch Otolaryng. 1965; 82: 522-6
|
|
|
|
|
|
30）Harrison DFN. Familial hemorrhagic telangiectasia. QJ Med. 1964; 129: 25-38
|
|
|
|
|
|
31）大久保公裕，八木聰明．オスラー病に対する超音波凝固切開装置の使用経験．耳喉頭頸. 1999; 71: 955-8
|
|
|
|
|
|
32）Mahoney EJ, Shapshay SM. Nd-YAG laser photocoagulation for epistaxis associated with hereditary hemorrhagic telangiectasia. Laryngoscope. 2005; 115: 373-5
|
|
|
|
|
|
33）市村恵一，中村直也，田中利善，他．オスラー病に対する鼻腔植皮術．耳鼻臨床．1994; 87: 895-900
|
|
|
|
|
|
34）Fiorella ML, Ross D, Henderson KJ, et al. Outcome of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia. Laryngoscope. 2005; 115: 301-5
|
|
|
|
|
|
35）Yaniv E, Preis M, Hadar T, et al. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: double-blind placebo-controlled clinical trial. Laryngoscope. 2009; 119: 284-8
|
|
|
|
|
|
36）Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high dose of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med. 2001; 345: 926
|
|
|
|
|
|
37）Miller F, Whiting J, Korzenik J, et al. Caution with use of hepatic embolization in the treatment of hereditary hemorrhagic telangiectasia. Radiology. 2000; 213: 928-30
|
|
|
|
|
|
38）Kitamura T, Tanabe S, Koizumi W, et al. Rendu-Osler-Weber disease successfully treated by argon plasma coagulation. Gastrointest Endsc. 2001; 54: 525-7
|
|
|
|
|
|
39）田中心和，坂口一彦，大西 裕，他．アルゴンプラズマ凝固療法がOsler-Rendu-Weber病の消化管病変に対して有用であった1例．Gastroenterol Endosc. 2006; 48: 31-6
|
|
|
|
|
|
40）Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999; 104: 1343-51
|
|
|
|
|
|
41）Choi EJ, Kim YH, Choe, S, et al. Enhanced responses to angiogenic cues underlie the pathogenesis of hereditary hemorrhagic telangiectasia 2. PloS One. 2013; 8: e63138. Doi: 10. 1371/journal. pone. 0063138
|
|
|
|
|
|
42）Lebrin F, Sprun S, Raymond K, et al. Thalidomide stimulates vessel mutation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nature Medicine. 2010; 16: 420-9
|
|
|
|
|
|
43）Chen, S, Karnezis, T, Davidson, TM. Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011; 121: 644-6
|
|
|
|
|